Project Grant R21AI193492
- This Project Grant award of $153,000.00, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), focuses on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research project has two novel approaches: 1) Evaluating the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure, and 2) Exploring a second approach outlined in Aim 2 (details not...
- This Project Grant award of $157,400 from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The primary objective is to establish the efficacy of Maroon Biotech's MP8800 copolymer in increasing 10-day and 30-day survival rates, as well as preserving gut barrier function, in a well-established rat model of GI-ARS. The research is...
- This $167,500 Project Grant awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat the gastrointestinal acute radiation syndrome (GI-ARS). The grant recipient, The Feinstein Institutes For Medical Research, will conduct research to demonstrate that MSP68 can mitigate GI-ARS by promoting the recovery of gut stem cells and reducing intestinal damage...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,000 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the mitochondrial serine/threonine phosphatase PGAM5 as a potential target for mitigating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to examine the role of PGAM5 in radiation-induced oxidative stress and modulation of Wnt/β-catenin...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) provides $149,008 to evaluate the use of PEG-BPEI as a potential mitigator against gastrointestinal acute radiation syndrome (GI-ARS). The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. will develop a murine model of partial body irradiation to study the effects of radiation on the GI tract while minimizing systemic...
- This $164,500 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasure drugs. The goal is to create an extracorporeal model based on healthy human GI tissue that can accurately assess the efficacy and safety of radiation mitigators, addressing limitations of...
- The National Institutes of Health (NIH) awarded a $156,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Georgetown University on August 11, 2025. The project, titled "Development of a Multiomic Biodosimetry Panel for Use During Sepsis and Antibiotic Treatment", aims to develop a novel panel of metabolomic and gene expression biomarkers to rapidly screen and provide accurate dose reconstruction for individuals exposed to ionizing radiation. This panel will...
- This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $470,309.00 to Chromologic LLC, a minority-owned small business in Monrovia, CA, to develop a genetically modified probiotic for mitigating radiation-induced gastrointestinal and hematopoietic injuries. The project aims to engineer a second-generation probiotic that can deliver a known mitigator, interferon-beta, to the gastrointestinal tract to...
- This federal Project Grant award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $158,716 to Duke University to conduct research on epigenetic mechanisms underlying intestinal stem cell fate conversion in response to severe radiation injury. The research aims to comprehensively examine the epigenetically-regulated and transcriptionally-dependent transitions, as well as the molecular...
- This Project Grant award, totaling $156,000.00, was provided by the Office of the Director of the U.S. Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The project aims to develop a novel, dual-specimen biomarker strategy to improve early detection of gastrointestinal acute radiation syndrome (GI-ARS) using angiotensin-converting enzyme 2 (ACE2) as an early tissue-specific biomarker. The study, conducted by...
The Project Grant titled "Engineered Microbes to Mitigate Intestinal Radiation Damage" was awarded by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $160,125 award to Baylor College of Medicine aims to explore the use of the microbiome to deliver growth factors that promote survival and proliferation of radioresistant intestinal stem cells. The objective is to assess a genetically modified Limosilactobacillus reuteri 6475 strain as a medical countermeasure to accelerate recovery from gastrointestinal acute radiation syndrome (GI-ARS) in a rodent model. The 2-year project period runs from August 1, 2025 to July 31, 2027, with the goal of supporting continued development of the engineered microbe as a potential general nuclear countermeasure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $160.1k | 7/30/25 |